Blueprint Medicines (BPMC) Commences $150M Offering of Common Stock

March 29, 2017 7:32 AM EDT Send to a Friend
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login